Cumulative incidence of relapse. (A) Cumulative incidence of relapse/progression by prior checkpoint inhibition at haplo-SCT.  Two-year relapse/progression rate was 22% in the no-CPI cohort and 4% in the CPI cohort (P = .098). (B) Cumulative incidence of relapse by prior checkpoint inhibition at haplo-SCT. Two-year relapse cumulative incidence was 20% in the no-CPI group vs 0% in the CPI group (P = .054).